Tisdag 3 Juni | 01:16:44 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-10 08:50 Bokslutskommuniké 2025
2025-11-07 09:00 Kvartalsrapport 2025-Q3
2025-08-22 09:00 Kvartalsrapport 2025-Q2
2025-06-16 N/A X-dag ordinarie utdelning BIBB 0.00 SEK
2025-06-13 N/A Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-06-17 - X-dag ordinarie utdelning BIBB 0.00 SEK
2024-06-14 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-15 - X-dag ordinarie utdelning BIBB 0.00 SEK
2023-06-14 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning BIBB 0.00 SEK
2022-06-14 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-15 - X-dag ordinarie utdelning BIBB 0.00 SEK
2021-06-14 - Årsstämma
2021-05-14 - Kvartalsrapport 2021-Q1
2021-02-15 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-06-12 - X-dag ordinarie utdelning BIBB 0.00 SEK
2020-06-11 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-27 - Kvartalsrapport 2019-Q2
2019-06-20 - X-dag ordinarie utdelning BIBB 0.00 SEK
2019-05-22 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-26 - Kvartalsrapport 2018-Q3
2018-08-27 - Kvartalsrapport 2018-Q2
2018-06-21 - Årsstämma
2018-05-21 - X-dag ordinarie utdelning BIBB 0.00 SEK
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-27 - Kvartalsrapport 2017-Q3

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
BiBBInstruments är verksamt inom medicinteknik. Bolaget utvecklar biopsiinstrument baserat på bolagets egenutvecklade teknologiplattform. Tekniken används huvudsakligen inom specialistsjukvården och kirurgavdelningar vid behandling av olika cancerformer. Produkterna säljs som engångsinstrument med framtagen borrfunktion och används vid stadiet av diagnostisering. Bolaget grundades 2013 och har sitt huvudkontor i Lund.
2025-05-22 08:55:00

BiBBInstruments AB ("BiBB" or the "Company") publishes a letter from the CEO, Fredrik Lindblad, due to the beginning of the subscription period for warrants of series TO 1. The CEO letter is available on BiBB's website.

In connection with the beginning of the subscription period for the warrants of series TO 1, the Company publishes a CEO letter. The CEO letter is available on BiBB's website: www.bibbinstruments.com.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB

BiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® - the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BIBB) is listed on Spotlight Stock Market.

 

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.